UC San Diego Health joins national research for maternal-fetal care
Business Announcement
Updates every hour. Last Updated: 31-May-2026 19:16 ET (31-May-2026 23:16 GMT/UTC)
Cambridge, MA, February 17, 2025 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies. The initiative builds on MSK’s global leadership in this field under the direction of Yelena Y. Janjigian, MD, Carroll and Milton Petrie Chair; Chief, GI Oncology; and Founding Director of the MSK GEC Therapeutics Accelerator, whose group has delivered multiple practice-changing advances in gastric and gastroesophageal junction cancers. Patrick Evans, BS, MBA, Senior Project Manager in the Janjigian Lab, will serve as the MSK project lead, supporting integration of scientific, operational, and translational efforts across teams.
MIT chemical engineers used AI to optimize the selection of codon sequences for protein drugs produced by yeast, which could reduce the costs of developing and manufacturing these drugs.
Subsidies enacted a year into the COVID-19 pandemic to expand eligibility and offset premium costs of insurance purchased on Affordable Care Act (ACA) marketplaces led to significant enrollment gains among eligible children ages 18 and under, Black and Hispanic individuals, and residents of rural areas, according to a new study by a researcher at the Johns Hopkins Bloomberg School of Public Health.